{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:28:01Z","timestamp":1778617681758,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["5K23HL148310-02"],"award-info":[{"award-number":["5K23HL148310-02"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["CSDA 2020095"],"award-info":[{"award-number":["CSDA 2020095"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00198-024-07268-1","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:02:16Z","timestamp":1729555336000},"page":"93-102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Alendronate preserves bone mineral density in adults with sickle cell disease and osteoporosis"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3082-9114","authenticated-orcid":false,"given":"Oyebimpe O.","family":"Adesina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac C.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e1bio","family":"Galv\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana C.","family":"de Moura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kleber Y.","family":"Fertrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babette S.","family":"Zemel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara T. Olalla","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"7268_CR1","doi-asserted-by":"publisher","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","volume":"4","author":"GJ Kato","year":"2018","unstructured":"Kato GJ, Piel FB, Reid CD et al (2018) Sickle cell disease. Nat Rev Dis Prim 4:18010","journal-title":"Nat Rev Dis Prim"},{"issue":"20","key":"7268_CR2","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1182\/blood-2017-10-808550","volume":"130","author":"FB Piel","year":"2017","unstructured":"Piel FB, Williams TN (2017) Subphenotypes of sickle cell disease in Africa. Blood 130(20):2157\u20132158","journal-title":"Blood"},{"key":"7268_CR3","unstructured":"CDC (2016) Sickle cell disease. [cited 2016; Available from: http:\/\/www.cdc.gov\/ncbddd\/sicklecell\/data.html.\u00a0Accessed\u00a009\/08\/2023"},{"key":"7268_CR4","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1100\/tsw.2008.157","volume":"8","author":"MH Steinberg","year":"2008","unstructured":"Steinberg MH (2008) Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology, and therapeutic approaches. Sci World J 8:1295\u20131324","journal-title":"Sci World J"},{"issue":"20","key":"7268_CR5","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1182\/blood-2015-04-641969","volume":"126","author":"LD Carbonare","year":"2015","unstructured":"Carbonare LD, Matte\u2019 A, Valenti MT et al (2015) Hypoxia-reperfusion affects osteogenic lineage and promotes sickle cell bone disease. Blood 126(20):2320\u20132328","journal-title":"Blood"},{"issue":"4","key":"7268_CR6","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1542\/peds.2004-2582","volume":"116","author":"AM Buison","year":"2005","unstructured":"Buison AM, Kawchak DA, Schall JI et al (2005) Bone area and bone mineral content deficits in children with sickle cell disease. Pediatrics 116(4):943\u2013949","journal-title":"Pediatrics"},{"issue":"5 Pt 1","key":"7268_CR7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1203\/pdr.0b013e318045bdca","volume":"61","author":"BS Zemel","year":"2007","unstructured":"Zemel BS, Kawchak DA, Ohene-Frempong K, Schall JI, Stallings VA (2007) Effects of delayed pubertal development, nutritional status, and disease severity on longitudinal patterns of growth failure in children with sickle cell disease. Pediatr Res 61(5 Pt 1):607\u2013613","journal-title":"Pediatr Res"},{"issue":"6","key":"7268_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/01.med.0000436192.25846.0b","volume":"20","author":"I Osunkwo","year":"2013","unstructured":"Osunkwo I (2013) An update on the recent literature on sickle cell bone disease. Curr Opin Endocrinol Diabetes Obes 20(6):539\u2013546","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"4","key":"7268_CR9","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1365-2141.2005.05476.x","volume":"129","author":"A Almeida","year":"2005","unstructured":"Almeida A, Roberts I (2005) Bone involvement in sickle cell disease. Br J Haematol 129(4):482\u2013490","journal-title":"Br J Haematol"},{"key":"7268_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.bone.2018.03.002","volume":"119","author":"A Teti","year":"2019","unstructured":"Teti A, Teitelbaum SL (2019) Congenital disorders of bone and blood. Bone 119:71\u201381","journal-title":"Bone"},{"key":"7268_CR11","doi-asserted-by":"crossref","unstructured":"Grimbly C, Escagedo PD, Jaremko J et al (2022)\u00a0Sickle cell bone disease and response to intravenous bisphosphonates in children. Osteoporos Int 33(11):2397\u20132408","DOI":"10.1007\/s00198-022-06455-2"},{"key":"7268_CR12","doi-asserted-by":"publisher","unstructured":"De Franceschi L, Gabbiani D, Giusti A et al (2020) Development of algorithm for clinical management of sickle cell bone disease: evidence for a role of vertebral fractures in patient follow-up. J Clin Med\u00a09(5):1601. https:\/\/doi.org\/10.3390\/jcm9051601","DOI":"10.3390\/jcm9051601"},{"issue":"1","key":"7268_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1182\/hematology.2019000038","volume":"2019","author":"OO Adesina","year":"2019","unstructured":"Adesina OO, Neumayr LD (2019) Osteonecrosis in sickle cell disease: an update on risk factors, diagnosis, and management. Hematol Am Soc Hematol Educ Program 2019(1):351\u2013358","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"7","key":"7268_CR14","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/pbc.20681","volume":"47","author":"A Lal","year":"2006","unstructured":"Lal A, Fung EB, Pakbaz Z, Hackney-Stephens E, Vichinsky EP (2006) Bone mineral density in children with sickle cell anemia. Pediatr Blood Cancer 47(7):901\u2013906","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"7268_CR15","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1111\/tmi.12211","volume":"18","author":"M Meeuwes","year":"2013","unstructured":"Meeuwes M, Souza de Carvalho TF, Cipolotti R et al (2013) Bone mineral density, growth, pubertal development and other parameters in Brazilian children and young adults with sickle cell anaemia. Trop Med Int Health 18(12):1539\u201346","journal-title":"Trop Med Int Health"},{"issue":"4","key":"7268_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/MAJ.0b013e3182893377","volume":"347","author":"P Adams-Graves","year":"2014","unstructured":"Adams-Graves P, Daniels AB, Womack CR, Freire AX (2014) Bone mineral density patterns in vitamin D deficient African American men with sickle cell disease. Am J Med Sci 347(4):262\u2013266","journal-title":"Am J Med Sci"},{"issue":"4","key":"7268_CR17","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/j.1365-2141.2006.06487.x","volume":"136","author":"M Sarrai","year":"2007","unstructured":"Sarrai M, Duroseau H, D\u2019Augustine J, Moktan S, Bellevue R (2007) Bone mass density in adults with sickle cell disease. Br J Haematol 136(4):666\u2013672","journal-title":"Br J Haematol"},{"issue":"5","key":"7268_CR18","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1590\/S1807-59322011000500015","volume":"66","author":"G Baldanzi","year":"2011","unstructured":"Baldanzi G, Traina F, Marques Neto JF et al (2011) Low bone mass density is associated with hemolysis in Brazilian patients with sickle cell disease. Clinics (Sao Paulo, Brazil) 66(5):801\u20135","journal-title":"Clinics (Sao Paulo, Brazil)"},{"issue":"3","key":"7268_CR19","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/tmi.12260","volume":"19","author":"AM Spinola-Castro","year":"2014","unstructured":"Spinola-Castro AM, Siviero-Miachon AA (2014) Low bone mineral density in patients with sickle cell anaemia (SCA) and short stature should be interpreted with caution. Trop Med Int Health: TM IH 19(3):364\u2013365","journal-title":"Trop Med Int Health: TM IH"},{"issue":"9","key":"7268_CR20","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1182\/bloodadvances.2018026047","volume":"3","author":"OO Adesina","year":"2019","unstructured":"Adesina OO, Gurney JG, Kang G et al (2019) Height-corrected low bone density associates with severe outcomes in sickle cell disease: SCCRIP cohort study results. Blood Adv 3(9):1476\u20131488","journal-title":"Blood Adv"},{"issue":"9","key":"7268_CR21","doi-asserted-by":"publisher","first-page":"e27228","DOI":"10.1002\/pbc.27228","volume":"65","author":"JS Hankins","year":"2018","unstructured":"Hankins JS, Estepp JH, Hodges JR et al (2018) Sickle Cell Clinical Research and Intervention Program (SCCRIP): a lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood. Pediatr Blood Cancer 65(9):e27228","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"7268_CR22","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jpain.2016.12.016","volume":"18","author":"C Dampier","year":"2017","unstructured":"Dampier C, Palermo TM, Darbari DS et al (2017) AAPT diagnostic criteria for chronic sickle cell disease pain. J Pain 18(5):490\u2013498","journal-title":"J Pain"},{"issue":"12","key":"7268_CR23","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1182\/bloodadvances.2020001851","volume":"4","author":"AM Brandow","year":"2020","unstructured":"Brandow AM, Carroll CP, Creary S et al (2020) American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv 4(12):2656\u20132701","journal-title":"Blood Adv"},{"key":"7268_CR24","doi-asserted-by":"publisher","first-page":"949535","DOI":"10.1100\/2012\/949535","volume":"2012","author":"SK Ballas","year":"2012","unstructured":"Ballas SK, Kesen MR, Goldberg MF et al (2012) Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorldJournal 2012:949535","journal-title":"ScientificWorldJournal"},{"issue":"1","key":"7268_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12887-019-1423-9","volume":"19","author":"V Mandese","year":"2019","unstructured":"Mandese V, Bigi E, Bruzzi P et al (2019) Endocrine and metabolic complications in children and adolescents with sickle cell disease: an Italian cohort study. BMC Pediatr 19(1):56","journal-title":"BMC Pediatr"},{"issue":"10","key":"7268_CR26","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1001\/jama.2014.10517","volume":"312","author":"BP Yawn","year":"2014","unstructured":"Yawn BP, Buchanan GR, Afenyi-Annan AN et al (2014) Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 312(10):1033\u20131048","journal-title":"JAMA"},{"issue":"3","key":"7268_CR27","doi-asserted-by":"publisher","first-page":"101369","DOI":"10.1016\/j.jocd.2023.101369","volume":"26","author":"JA Shepherd","year":"2023","unstructured":"Shepherd JA (2023) Positions of The international society for clinical densitometry and their etiology: a scoping review. J Clin Densitom 26(3):101369","journal-title":"J Clin Densitom"},{"issue":"10","key":"7268_CR28","doi-asserted-by":"publisher","first-page":"e0258638","DOI":"10.1371\/journal.pone.0258638","volume":"16","author":"RV Masese","year":"2021","unstructured":"Masese RV, Bulgin D, Knisely MR et al (2021) Sex-based differences in the manifestations and complications of sickle cell disease: report from the sickle cell disease implementation consortium. PLoS One 16(10):e0258638","journal-title":"PLoS One"},{"issue":"4","key":"7268_CR29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1177\/0193945918768277","volume":"41","author":"AM Gallo","year":"2019","unstructured":"Gallo AM, Patil C, Adeniyi T et al (2019) Health-related quality of life and personal life goals of adults with sickle cell disease after hematopoietic stem cell transplantation. West J Nurs Res 41(4):555\u2013575","journal-title":"West J Nurs Res"},{"issue":"3","key":"7268_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.coph.2006.03.005","volume":"6","author":"FP Coxon","year":"2006","unstructured":"Coxon FP, Thompson K, Rogers MJ (2006) Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 6(3):307\u2013312","journal-title":"Curr Opin Pharmacol"},{"issue":"Suppl 3","key":"7268_CR31","first-page":"600","volume":"71","author":"TB Cico","year":"2013","unstructured":"Cico TB, Kullolli S, Harizi I et al (2013) SAT0381 The use of bisphosphonates in the treatment of low bone mineral density in adults with sickle cell anemia. Ann Rheum Dis 71(Suppl 3):600\u2013601","journal-title":"Ann Rheum Dis"},{"key":"7268_CR32","first-page":"1","volume":"843","author":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis","year":"1994","unstructured":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis (1994) Report of a WHO Study Group. World Health Organ Tech Rep Ser 843:1\u2013129","journal-title":"World Health Organ Tech Rep Ser"},{"issue":"5","key":"7268_CR33","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM et al (2019) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 104(5):1595\u20131622","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"7268_CR34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.htct.2020.09.154","volume":"44","author":"AH Santo","year":"2022","unstructured":"Santo AH (2022) Sickle cell disease related mortality in Brazil, 2000\u20132018. Hematol Transfus Cell Ther 44(2):177\u2013185","journal-title":"Hematol Transfus Cell Ther"},{"issue":"FEB","key":"7268_CR35","first-page":"77","volume":"8","author":"V Jeney","year":"2017","unstructured":"Jeney V (2017) Clinical impact and cellular mechanisms of iron overload-associated bone loss. Front Pharmacol 8(FEB):77","journal-title":"Front Pharmacol"},{"key":"7268_CR36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.bone.2018.02.019","volume":"119","author":"RJ Valderr\u00e1bano","year":"2019","unstructured":"Valderr\u00e1bano RJ, Wu JY (2019) Bone and blood interactions in human health and disease. Bone 119:65\u201370","journal-title":"Bone"},{"key":"7268_CR37","doi-asserted-by":"publisher","first-page":"1302014","DOI":"10.3389\/fpain.2023.1302014","volume":"4","author":"J Gollamudi","year":"2023","unstructured":"Gollamudi J, Karkoska KA, Gbotosho OT et al (2023) A bone to pick-cellular and molecular mechanisms of bone pain in sickle cell disease. Front Pain Res (Lausanne) 4:1302014","journal-title":"Front Pain Res (Lausanne)"},{"key":"7268_CR38","unstructured":"FOSAMAX\u00ae (Package Insert) (2015) Merck and Co., I.W.S., NJ:2015"},{"issue":"3","key":"7268_CR39","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1556\/APhysiol.97.2010.3.5","volume":"97","author":"DM Bolarin","year":"2010","unstructured":"Bolarin DM, Azinge EC (2010) Osteocalcin and specific markers of bone resorption in sickle cell disease. Acta Physiol Hung 97(3):290\u2013296","journal-title":"Acta Physiol Hung"},{"issue":"11","key":"7268_CR40","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/ajh.21856","volume":"85","author":"E Nur","year":"2010","unstructured":"Nur E, Mairuhu W, Biemond BJ et al (2010) Urinary markers of bone resorption, pyridinoline and deoxypyridinoline, are increased in sickle cell patients with further increments during painful crisis. Am J Hematol 85(11):902\u2013904","journal-title":"Am J Hematol"},{"key":"7268_CR41","doi-asserted-by":"publisher","first-page":"102369","DOI":"10.1016\/j.bcmd.2019.102369","volume":"80","author":"OO Adesina","year":"2020","unstructured":"Adesina OO, Jenkins IC, Wu QV et al (2020) Urinary cross-linked carboxyterminal telopeptide, a bone resorption marker, decreases after vaso-occlusive crises in adults with sickle cell disease. Blood Cells Mol Dis 80:102369","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"7268_CR42","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","volume":"22","author":"S Vasikaran","year":"2011","unstructured":"Vasikaran S, Eastell R, Bruyere O et al (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22(2):391\u2013420","journal-title":"Osteoporos Int"},{"issue":"3","key":"7268_CR43","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.htct.2020.06.009","volume":"43","author":"AM Queiroz","year":"2021","unstructured":"Queiroz AM, Lobo CLC, Ballas SK (2021) Menopause in Brazilian women with sickle cell anemia with and without hydroxyurea therapy. Hematol Transfus Cell Ther 43(3):386\u2013388","journal-title":"Hematol Transfus Cell Ther"},{"key":"7268_CR44","unstructured":"Looker AC, Borrud LG, Hughes JP et al (2012) Lumbar spine and proximal femur bone mineral density, bone mineral content, and bone area: United States, 2005\u20132008. Vital Health Stat 11(251):1\u201313"},{"issue":"16","key":"7268_CR45","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1182\/bloodadvances.2017005256","volume":"1","author":"O Adesina","year":"2017","unstructured":"Adesina O, Brunson A, Keegan THM, Wun T (2017) Osteonecrosis of the femoral head in sickle cell disease: prevalence, comorbidities, and surgical outcomes in California. Blood Adv 1(16):1287\u20131295","journal-title":"Blood Adv"},{"issue":"2","key":"7268_CR46","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.cyto.2014.10.025","volume":"71","author":"S Ishtiaq","year":"2015","unstructured":"Ishtiaq S, Edwards S, Sankaralingam A et al (2015) The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells. Cytokine 71(2):154\u2013160","journal-title":"Cytokine"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07268-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-024-07268-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07268-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T23:02:34Z","timestamp":1736290954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-024-07268-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["7268"],"URL":"https:\/\/doi.org\/10.1007\/s00198-024-07268-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]},"assertion":[{"value":"18 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We performed this study in accordance with the ethical standards in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}